When Prevention Meets Progress, How Does Resilience Take Shape in Mozambique’s Clinics?

In the quiet weave of public health, there are threads that bind prevention and cure like light unravelling the edges of a shadow — subtle yet profound. When people living with HIV embark on antiretroviral therapy, they carry not only a promise of restored immunity but also a heightened vulnerability to illnesses that seize on weakened defenses. Among these, tuberculosis has long been a silent traveller, its footprint large where immune resilience is low and protective networks thin.

A new study from Mozambique draws this interplay into gentle focus, measuring how the embrace of tuberculosis preventive therapy shapes outcomes for people living with HIV (PLHIV) who recently began antiretroviral therapy. Tuberculosis — a bacterial disease that still ranks among the leading causes of illness and death in PLHIV globally — persists even amid progress, reminding healthcare systems that vigilance and prevention must walk hand in hand with treatment.

In Mozambique, a nation where HIV and tuberculosis converge in complex patterns, researchers analysed data on over 340,000 PLHIV who began antiretroviral therapy between 2021 and 2022. Within this large cohort, completion of tuberculosis preventive therapy (TPT) was associated with markedly lower rates of subsequent TB diagnosis compared with those who did not start or did not complete the full course of TPT.

The study’s findings illuminate how protection unfolds over time: those who completed TPT had a TB diagnosis rate of approximately 3.1 per 1,000 person‑years, while rates were significantly higher — about 11.0 per 1,000 person‑years — for those with incomplete TPT, and 21.6 per 1,000 person‑years for those who did not start TPT at all.

These differences reflect not just numbers but the lived experience of people navigating treatment journeys that begin with hope and are sustained through access to comprehensive care. TPT, in this context, does more than interrupt the progression toward active disease — it extends the time between starting HIV therapy and the onset of tuberculosis, offering a cushion of resilience.

Yet the narrative does not end with a single intervention. Even among those who completed TPT, certain groups showed somewhat elevated risk for TB: men, younger and older age brackets, individuals with unsuppressed HIV viral loads, lower CD4 cell counts, and those in Mozambique’s Southern Region had higher incidence in this group. These nuances suggest that tailored attention — whether through enhanced monitoring or adapted preventive strategies — may help close remaining gaps.

Globally, efforts to expand TPT coverage among PLHIV reflect a shared commitment to reducing TB burden and building health systems that are both proactive and responsive. The World Health Organization notes that countries with high TB/HIV burdens, including Mozambique, have prioritised preventive therapy alongside antiretroviral treatment to curb the dual epidemic.

In Mozambique, civil society, healthcare workers and international partners have also been central to scaling up preventive treatment in recent years, contributing to broader coverage and heightened awareness of TB risks among those living with HIV.

In simple terms, evidence from Mozambique suggests that tuberculosis preventive therapy significantly lowers the incidence of TB among people living with HIV who recently started antiretroviral therapy. Completion of TPT is linked with reduced TB rates compared with incomplete or absent preventive treatment, even while some subgroups remain at higher risk.

AI Image Disclaimer Graphics are AI‑generated and intended for representation, not reality.

Sources: Centers for Disease Control and Prevention – Emerging Infectious Diseases World Health Organization CDC Global HIV & TB regional overview Additional related research summaries (turn0search0,turn0search1,turn0search5)